The regulatory circuits that orchestrate mammalian myoblast cell fusion during myogenesis are poorly understood. The transcriptional activity of FoxO1a directly regulates this process, yet the molecular mechanisms governing FoxO1a activity during muscle cell differentiation remain unknown. Here we show an autoregulatory loop in which FoxO1a directly activates transcription of the cyclic GMP-dependent protein kinase I (cGKI) gene and where the ensuing cGKI activity phosphorylates FoxO1a and abolishes its DNA binding activity. These findings establish the FoxO1a-to-cGKI pathway as a novel feedback loop that allows the precise tuning of myoblast fusion. Interestingly, this pathway appears to operate independently of muscle cell differentiation programs directed by myogenic transcription factors.
Fusion of cell membranes is required for the proper function and morphogenesis of several mammalian cell types, including macrophages, trophoblasts, spermatozoa and oocytes, and myoblasts that form skeletal muscle. While the mechanisms regulating intracellular membrane fusion events have been studied in some detail (4, 17) , very little is known regarding the mechanisms governing mammalian cell-to-cell fusion events.
Complex programs orchestrate myogenesis, which involve coordinated myogenic cell migration, recognition, adhesion, alignment, and finally membrane fusion. The FoxO family of transcription factors (FoxO1a, FoxO3, and FoxO4a) regulates diverse cellular responses, including apoptosis, cell cycle arrest, differentiation, DNA repair, and oxidative stress (1, 3, 7, 34) . While the ability of FoxO's to regulate divergent processes such as apoptosis and differentiation seems somewhat paradoxical, some of the cellular alterations associated with skeletal muscle cell differentiation do share a high degree of similarity with many phenotypic changes usually associated with apoptosis. Indeed, cytoskeleton remodeling and actin fiber disassembly are features shared by these two processes (10, 14, 16, 29, 32) , and myosin light chain kinase, a conserved regulator of muscle cell contraction, is also essential for the blebbing of cell membranes observed during apoptosis (23) . Furthermore, matrix metalloproteinases are required for both apoptosis and muscle cell fusion (28, 36) , and activation of caspase 3, a key effector apoptotic protease, is also required for skeletal muscle cell differentiation (11) .
FoxO1a is essential for normal development, as evidenced by the fact that knockout mice lacking FoxO1a die at embryonic day 9.5 (E9.5) to E10.5 due to defects in vasculogenesis, whereas targeted deletions of the close FoxO1a homologs FoxO3 and FoxO4a lead to limited, if any, developmental phenotypes (8, 18) . Interestingly, endothelial cells lacking FoxO1a fail to reorganize into vessel-like structures when stimulated with vascular endothelial growth factor (12) , suggesting that FoxO1a directs cytoskeleton remodeling and cell-cell interactions during the formation of the vasculature. In addition, FoxO1a is both necessary and sufficient to regulate myoblast cell fusion ex vivo (5, 25) .
The transcriptional activity of FoxO1a also appears to be regulated by phosphorylation events during myoblast differentiation (5, 25) , and conventionally this has been thought to be directed by Akt serine/threonine kinases that phosphorylate FoxO transcription factors, which provokes their nuclear export and destruction by the proteasome (22) . However, in primary myoblasts and in the myoblast cell line C2C12, phosphorylation of FoxO1a occurs independently of the phosphatidylinositol 3-kinase/Akt pathway, suggesting that other kinases harness FoxO1a transcriptional activity during myogenic differentiation (5, 25) . Indeed, inactivation of the Rho-associated kinase ROCK has been demonstrated to be a prerequisite for FoxO1a nuclear translocation and fusion of C2C12 cells (25) . In addition, FoxO3 is phosphorylated by IB kinase independently of Akt, and this also causes its ubiquitin-dependent degradation (20) . These findings support the concept that divergent signaling pathways impinge upon the transcriptional activity of FoxO transcription factors, thereby regulating their diverse and cell type-specific functions.
Here we report that cyclic GMP-dependent protein kinase I (cGKI) is a regulator of FoxO1a activity during muscle cell fusion. Interestingly, upon muscle cell differentiation, FoxO1a is shown to directly activate cGKI transcription. In turn, cGKI then harnesses FoxO1a activity by phosphorylating residues juxtaposed to the FoxO1a DNA binding domain, thus abolishing the ability of FoxO1a to bind to its response elements. cGKI also promotes relocalization of FoxO1a into the cytoplasm. These results therefore suggest that a FoxO1a-to-cGKI pathway fine-tunes the rates of myoblast cell fusion.
MATERIALS AND METHODS
Yeast two-hybrid screen. The CytoTrap system (Stratagene) was used to perform the yeast two-hybrid screen following the supplier's protocol. Particular care was taken to avoid reversion of the cdc25H yeast strain. FoxO1a was used as bait and cloned into the pSOS vector (Stratagene). A stable pSOS-FoxO1a cdc25H yeast strain was first established before screening with the commercially available heart cDNA target library (Stratagene).
Mouse primary myoblast isolation and culture, and culture of C2C12 cells. Primary myoblasts were isolated and cultured from 6-day-old cGKI wild-type and knockout littermates (35) as described previously (5) . Cell fusion experiments using CellTracker probes (Molecular Probes) were performed following the supplier's protocol. The two dyes used were CellTracker Green CMFDA and CellTracker Orange CMTMR. The C2C12 cell line was obtained from the American Type Culture Collection. Passage-1 and -2 cells were used for the experiments, and particular care was taken to avoid overgrowth by passing the cells before they reached 50 to 60% confluence. Failure to do so quickly induced differentiation and a partial or complete loss of differentiation potential in subsequent passages. C2C12 cells were cultured in Dulbecco's modified Eagle medium (DMEM)-10% fetal bovine serum by following standard protocols. Differentiation was induced by either growing the cells to confluence or transferring them to DMEM containing 2% horse serum (25) .
RT-PCR, protein analysis, and ChIP experiments. Reverse transcription-PCR (RT-PCR) and Western blotting were performed using standard protocols. Sequences of primers are available upon request. An anti-FoxO1a (FKHR) antibody was purchased from Cell Signaling Technology, an anti-green fluorescent protein (GFP) antibody from Molecular Probes, activated vasodilator-stimulated phosphoprotein (VASP) (serine 239) from nanoTools, an anti-FLAG antibody from Sigma, and an anti-cGKI (PKG) antibody from StressGen; the MF20 (myosin heavy chain) antibody was a gift from D. A. Fischman. Chromatin immunoprecipitation (ChIP) experiments were performed using the chromatin immunoprecipitation assay kit from Upstate Biotechnology following the supplier's protocol. The primers used to amplify the regions containing the FoxO1a binding sites surrounding the cGKI␣ promoter area were cGKI-7.0kb/F (5Ј-GT GCCTTATGCTTAGCAATGAG-3Ј), cGKI-6.7kb/R (5Ј-CACTTGAAGACGG TGAGTCCT-3Ј), cGKI ϩ6.5kb/F (5Ј-GTGCATGAGACTCATTTCATGG-3Ј), and cGKI-ϩ6.8kb/R (5Ј-GACGCAGGG TGAAGGGTAGGT-3Ј).
Phosphorylation and gel retardation assays. The various domains of FoxO1a protein used for phosphorylation assays were produced either in BL21 bacteria (Stratagene) or in a coupled transcription-reticulocyte lysate translation kit (Promega). cGKI kinase was purchased from Promega, and kinase assays were performed according to the supplier's protocol. (13) . These assays were performed using in vitro-translated FoxO1a proteins due to the high instability of recombinant FoxO1a proteins in bacteria.
Luciferase assays. Luciferase reporters carrying the region from kb Ϫ7.0 to Ϫ6.7 or from kb ϩ6.5 to ϩ6.8 of the cGKI␣ promoter (referred to below as the Ϫ7.0/Ϫ6.7-kb or ϩ6.5/ϩ6.8-kb region, respectively) containing the FoxO1a binding sites were generated by inserting PCR-amplified fragments upstream of the minimal promoter (KpnI/XhoI sites) of the pGL3-basic firefly luciferase vector (Promega). Primers used were cGKI-7.0kb/F (5Ј-ggggtaccGTGCCTTATGCTT AGCAATGAG-3Ј), cGKI-6.7kb/R (5Ј-ccgctcgagCACTTGAAGACGGTGAGT CCT-3Ј), cGKIϩ6.5kb/F (5Ј-ggggtaccGTGCATGAGACTCATTTCATGG-3Ј), and cGKI-ϩ6.8kb/R (5Ј-ccgctcgagGACGCAGGGTGAAGGGTAGGT-3Ј). KpnI (5Ј) and XhoI (3Ј) sites (lowercase) were added for cloning purposes. Myoblasts (primary myoblasts or C2C12 cells) were transiently transfected with either reporter construct using FuGene6 or Lipofectamine 2000 following the supplier's protocol. Luciferase detection was performed using the Luciferase Assay System from Promega by following the manufacturer's recommendations. A secreted alkaline phosphatase (SEAP) reporter was cotransfected (100 ng per transfection) to normalize for transfection efficiency, and SEAP activity was determined as described previously (5) .
Virus production, myoblast transduction, and cell sorting. D. Persons, SJCRH, provided the murine stem cell virus (MSCV)-internal ribosome entry site (IRES)-GFP vector. All FoxO1a point mutations were introduced using standard molecular biology protocols (2) . Myoblasts were transduced using standard techniques, and 2 days after infection, cells expressing GFP were sorted by flow cytometry.
Mice. cGKI
ϩ/Ϫ mice (35) were kindly provided by Franz Hofmann and Robert Feil (Pharmacology and Toxicology Institute, Munich, Germany). Mice were maintained at SJCRH under specific-pathogen-free conditions by following the Institutional Animal Care and Use Committee guidelines.
RESULTS AND DISCUSSION
FoxO1a interacts with cyclic GMP-dependent kinase I. To identify possible regulators of FoxO1 activity during muscle cell fusion, we performed a yeast two-hybrid screen using fulllength FoxO1a as bait. These analyses identified the catalytic subunit of cGKI as a prey for FoxO1a. Two independent clones encoding the C-terminal amino acids 414 and 353 of cGKI interacted strongly with FoxO1a in these assays. To determine whether FoxO1a-cGKI interactions were also detectable in muscle cells, we performed coimmunoprecipitation experiments with C2C12 cells engineered to overexpress Flag-FOXO1A and the kinase domain of cGKI. Notably, FoxO1a was coimmunoprecipitated with the kinase domain of cGKI by using an anti-cGKI antibody (Fig. 1A) . Available antibodies to FoxO1a are poor at immunoprecipitating endogenous levels of FoxO1a, so we utilized Flag-tagged FoxO1a in our experiments. In differentiating C2C12 cells, endogenous cGKI was coimmunoprecipitated with overexpressed Flag-tagged FoxO1a by using an anti-Flag antibody (Fig. 1B) . Therefore, FoxO1a and cGKI do form a complex in muscle progenitors.
These findings suggested that cGKI might regulate FoxO1a functions. Interestingly, after receiving differentiation cues, myoblasts show an essential and rapid spike in intracellular levels of cyclic GMP (cGMP) prior to fusion (9) . Moreover, cGKI belongs to the AGC (cAMP-dependent protein kinase/ protein kinase G/protein kinase C) family of protein kinases (26) and appears to contribute to the control of cytoskeleton remodeling by phosphorylating and inactivating the VASP (6, 15, 31) . We therefore assessed the functional importance of the cGKI-FoxO1a interaction during myoblast fusion. Cyclic GMP-dependent kinase I is a direct transcriptional target of FoxO1a. During muscle cell differentiation. cGMP levels transiently increase in a temporal manner that follows the nuclear translocation and transcriptional activation of FoxO1a (5, 9). We therefore hypothesized that cGKI might be a direct transcription target of FoxO1a during myoblast fusion. The cGKI gene encodes two isoforms (␣ and ␤), which differ only in the sequences encoded by their respective first exons. An additional cGKI family member, cGKII, also possesses cGMP-dependent protein kinase activity (27) , but cGKI␤ and cGKII were not significantly expressed in proliferating or differentiating myoblasts (data not shown). In contrast, cGKI␣ mRNA and protein were robustly induced in primary myoblasts after the induction of differentiation ( Fig. 2A to D) . cGKI␣ induction was also observed in differentiating C2C12 cells (see Fig. 4A ).
The early-embryonic lethality of the FoxO1a knockout (at E9.5 to 10.5 [18] ) precluded analysis of cGKI␣ expression in these knockout myoblasts, and repeated attempts to knock down endogenous FoxO1a expression using FoxO1a-directed short hairpin RNA failed to show effects on FoxO1a expression (data not shown). However, we were able to analyze the effects of a dominant-negative form of FoxO1a, FoxO1a-⌬TA (lacking the FoxO1a transactivation domain, which prevents myoblast fusion [5] ), upon cGKI␣ expression in transduced myoblasts. Importantly, up-regulation of cGKI␣ was abolished in myoblasts expressing dominant-negative FoxO1a-⌬TA ( Fig.   2A and B). Conversely, expression of the dominant-active FoxO1a-TM, which harbors alanine substitutions at the three known Akt sites of FoxO1a (Thr 24 , Ser 256 , and Ser 319 ), and which dramatically accelerates the rate of myoblast cell fusion (5), led to 2.5-fold induction of cGKI␣ mRNA and cGKI␣ protein even in proliferating myoblasts and augmented this response following the induction of differentiation ( Fig. 2C and  D) . Therefore, although the use of dominant versions of FoxO1a could have off-target effects, the data are consistent with the model where FoxO1a regulates, directly or indirectly, cGKI␣ expression.
To address whether cGKI␣ is a direct transcriptional target of FoxO1a, we first surveyed the cGKI genomic sequence for the presence of FoxO1a consensus binding sites. Indeed, two regions, of 300 bp each (Ϫ7.0/Ϫ6.7 kb and ϩ6.5/ϩ6.8 kb), surrounding exon 1 of the cGKI␣ gene harbor several TTGT TTAC (13) FoxO DNA binding sites. These sites are also present at similar distances from exon 1 in the human, rat, and fugu cGKI␣ promoter-regulatory regions (data not shown). We therefore used ChIP assays to investigate whether FoxO1a occupied these elements in myoblasts in a differentiationdependent manner. In primary myoblasts expressing Flagtagged FoxO1a, ChIP with an anti-FLAG antibody demonstrated that FoxO1a was recruited to these sites in the cGKI␣ promoter region within 6 h following induction of differentiation (Fig. 3A) . Furthermore, the activity of luciferase reporter constructs containing either of these elements upstream of a minimal promoter was dramatically induced in C2C12 myoblasts after induction of differentiation (Fig. 3B) . However, the same regions deleted for the FoxO binding sites failed to show any induction of luciferase activity (Fig. 3B) . Therefore, FoxO1a is recruited to FoxO binding sites in the cGKI␣ gene at the initial phase of myoblast differentiation, which coincides with the induction of cGKI␣ transcription. However, when we attempted to induce C2C12 muscle cell differentiation by complete serum withdrawal, as described by others (19), we were unable to detect significant increases in luciferase activity (Fig.  3B ). This apparent discrepancy was due to a dramatic induction of apoptosis by following this method of differentiation (Fig. 3C) . Thus, by following the conventional method for induction of differentiation ex vivo, i.e., placing the cells in 2% horse serum, FoxO1a is regulated in C2C12 cells in a fashion similar to that observed in primary myoblasts, a finding recently corroborated by others (25) . Cyclic GMP-dependent kinase I is activated during myoblast differentiation. It has been demonstrated previously that a spike of the second messenger cGMP is observed prior to myoblast fusion (9) . Using C2C12 cells as a model, we followed the timing of the expression of FoxO1a and cGKI␣ during differentiation and compared this with phosphorylation of a known cGKI target, the cytoskeletal protein VASP, by analyz- ing the status of VASP phosphorylation on serine-239, a consensus cGKI site (33) . As expected (5), we observed a rapid increase in the steady-state levels of FoxO1a, which was immediately followed by a subsequent increase in cGKI levels, and then by increases in the muscle cell differentiation markers myogenin and myosin heavy chain and in muscle cell fusion (Fig. 4) . Interestingly, after 3 days, the levels of FoxO1a rapidly diminished, whereas high levels of cGKI were sustained in differentiated myocytes; therefore, FoxO1a activity is required to initiate, but not sustain, cGKI expression during myoblast differentiation (Fig. 4) . Further, while there was no detectable phospho-VASP-S 239 in proliferating myoblasts, there was a striking increase in the phosphorylation of VASP on serine-239 2 days after the induction of differentiation, and this peaked at 3 days and declined thereafter (Fig. 4) . These findings are consistent with a model where FoxO1a activity is required to induce cGKI expression, and cGKI activity is then induced by a spike of cGMP and is associated with subsequent downregulation of FoxO1a expression. Since dominant-active FoxO1a greatly augments myoblast fusion (5), such a scenario would fine-tune FoxO1a activity to properly coordinate muscle cell fusion.
Cyclic GMP-dependent kinase I phosphorylates FoxO1a. The timing of cGKI␣ expression and activity, and subsequent down-regulation of FoxO1a, during muscle cell differentiation and fusion suggested that FoxO1a itself might be a target of cGKI␣. To address whether cGKI␣ might phosphorylate FoxO1a, we tested whether purified recombinant FoxO1a was phosphorylated by cGKI␣. Indeed, in vitro kinase assays demonstrated that FoxO1a was robustly phosphorylated by cGKI␣ (Fig. 5A) (22) , but there is little evidence for Akt modifications of FoxO1a playing an important role during muscle cell differentiation, since Akt is not activated during myoblast cell differentiation, and dominant-negative Akt does not affect FoxO1 levels, phosphorylation, localization, or transcriptional activity, nor does it affect myoblast cell differentiation (5) . Indeed, the dominant-active FoxO1a-TM mutant, which harbors alanine substitutions at these three Akt phosphorylation sites, was phosphorylated equally well by cGKI␣ (Fig. 5A ). To define which regions of FoxO1a were phosphorylated by cGKI␣, protein fragments covering the entire FoxO1a amino acid sequence were used as substrates in in vitro kinase assays with cGKI␣. These analyses showed that fragments containing Thr 24 , Ser 256 , or Ser 319 were not significantly phosphorylated by cGKI␣ (Fig. 5B and C) , whereas fragments containing regions 1 and 2 were excellent phosphorylation substrates for cGKI␣ (Fig. 5C) . To pinpoint the positions of these phosphorylation sites, we then used peptides spanning these two domains, using 9-to 12-mers or their nonphosphorylatable counterparts (with serine or threonine residues replaced by alanine) as in vitro cGKI substrates (data not shown). Peptides from region 1 containing Ser 152-155 or Ser 184 were robust cGKI substrates. Interestingly, the Ser 152-155 residues are unique to FOXO1a (not present in FOXO3 and FOXO4a) and are located immediately N-terminal to the DNA binding domain, whereas Ser 184 lies in the center of the second ␣-helix of the FoxO1a DNA binding domain and is absent in FOXO3 (Fig.  5B) . A peptide containing Ser 266 and Ser 268 , residing in the center of the second nuclear localization signal (NLS) of FoxO1a, a phosphorylation hot spot of FoxO transcription factors (34) , was also weakly phosphorylated by cGKI (Fig. 5B  and C) . Therefore, FoxO1a can be phosphorylated by cGKI␣.
Phosphorylation of FoxO1a by cyclic GMP-dependent kinase I inhibits its DNA binding activity. To evaluate the functional consequences of FoxO1a phosphorylation by cGKI␣, FoxO1a mutants harboring nonphosphorylatable or phosphomimetic amino acid substitutions were generated. FoxO1a mutants with Ser 266 , Ser 268 , or Ser 266/268 mutations showed no defects in nuclear-cytoplasmic shuttling or nuclear localization when expressed in differentiating primary myoblasts, and these cells also displayed no alterations in their rates of growth or differentiation or myoblast cell fusion (data not shown). However, we reasoned that cGKI phosphorylation sites in and around the FoxO1a DNA binding domain, Ser were replaced by alanine) was poorly phosphorylated by cGKI␣ in vitro (Fig. 5D) ; therefore, these serines are the major cGKI␣ phosphorylation sites.
We next assessed the effects of cGKI phosphorylation on the ability of FoxO1a-cGKI Mut.A to bind to an oligonucleotide containing a consensus FoxO1a DNA binding site (13) . Importantly, while in vitro-translated FoxO1a readily bound to its cognate DNA binding site in EMSA, FoxO1a phosphorylated by cGKI␣ in vitro did not (Fig. 6A and B) . To exclude the possibility that the cGKI␣ interaction might simply mask the FoxO1a DNA binding domain, we also tested whether heatinactivated cGKI␣ blocked the ability of FoxO1a to bind to its recognition element. This was not the case, and furthermore, treatment of FoxO1a that had been previously phosphorylated by cGKI␣ with lambda phosphatase restored the ability of FoxO1a to bind to its recognition element (Fig. 6C) . The inactivation of cGKI and the effectiveness of lambda phosphatase were confirmed using in vitro kinase assays (data not shown (Fig. 6D) . In addition, nonphosphorylatable versions of FoxO1a, both FoxO1a-TM and FoxO1a-cGKI Mut.A , did not show any reduction in their DNA binding activity by EMSA after exposure to active cGKI␣ kinase (data not shown). Finally, the specific FoxO1a band shift could be competed by adding excess cold probe (Fig. 6B and  D) and was supershifted by a FoxO1a-specific antibody (Fig.  6C) . Therefore, cGKI␣-mediated phosphorylation of FoxO1a abolishes its DNA binding activity.
Together these findings suggested that cGKI␣ kinase activity might impair FoxO1a functions in directing muscle cell fusion. To test this notion, C2C12 cells were transiently transfected with a constitutively active form of cGKI (cGKI-CA, where the N-terminal cGMP regulatory domain has been deleted [21] ). Constitutively active cGKI impaired the activation of the FoxO1a-responsive ϩ6.5/ϩ6.8-kb cGKI␣ luciferase reporter after induction of differentiation (Fig. 7A) . By contrast, cGKI-CA failed to impair the induction of this promoterreporter when cells were cotransfected with a vector expressing FoxO1a-cGKI Mut.A (the cGKI unphosphorylatable form of FoxO1a) (Fig. 7A) . As expected, the ϩ6.5/ϩ6.8-kb luciferase reporter deleted for the FoxO binding sites failed to show any activity and also was not affected by overexpression of FoxO1a or cGKI-CA ( Fig. 3B and 7A ; also data not shown). Identical findings were obtained by evaluating the regulation of a synthetic promoter-reporter that contained concatemerized FoxO1a binding sites upstream of a minimal promoter (data not shown) (5). We were unable to assess the long-term effects of forced overexpression of cGKI-CA on muscle cell differentiation or fusion, since it was toxic in both primary myoblasts and C2C12 cells. However, immunofluorescence analyses of C2C12 cells transiently expressing cGKI-CA suggested that activated cGKI␣ had rather dramatic effects on the morphology of these cells also overexpressing FoxO1a, with reductions in overall cell size relative to nontransduced cells (Fig. 7B) . In addition, cells expressing cGKI-CA showed an accumulation of FoxO1a in the cytoplasm compared to untransfected cells (Fig.  7B) , consistent with a model in which cGKI␣-mediated phosphorylation of FoxO1a at residues within and around its DNA binding domain inhibits its binding to DNA. To confirm the effects of activated cGKI␣ on FoxO1a localization, 293T cells, which are resistant to the toxic effects of cGKI-CA, were transiently transfected with FoxO1a with or without cGKI-CA. In cells expressing FoxO1a alone, FoxO1a was distributed throughout the cell, but in those also overexpressing cGKI-CA, there was a clear exclusion of FoxO1a from the nucleus (Fig. 8A) . These findings predicted that there would be clear differences in subcellular localization between the phosphomimetic FoxO1a-cGKI MutD mutant and the noncGKI␣-phosphorylatable mutant. Indeed, these experiments showed that that the alanine mutant FoxO1a-cGKI MutA was localized throughout the cell whereas the aspartic acid mutant FoxO1a-cGKI MutD was excluded from nuclei ( Fig. 8B) . Thus, cGKI␣ modifies FoxO1a functions at two levels, by directly impairing its ability to bind to its recognition element and by relocalizing FoxO1a into the cytoplasm, events that are both consistent with an important role for cGKI␣ in harnessing FoxO1a-driven myoblast fusion.
Cyclic GMP-dependent kinase I-deficient primary myoblasts display excessive cell fusion. The timing of FoxO1a-dependent expression of cGKI␣, together with the pre-fusion spike in the levels of intracellular cGMP that accompanies muscle cell differentiation (9) , should trigger cGKI␣ kinase activity. In turn, cGKI␣ should then phosphorylate FoxO1a to harness its activity and control rates of myoblast fusion. To confirm that cGKI is an essential regulator of muscle fusion, we isolated P6 primary myoblasts from cGKI Ϫ/Ϫ mice and compared their ex vivo growth and differentiation characteristics with those of myoblasts of wild-type littermates. cGKI accelerated rate of fusion, with some myotubes containing well over 75 nuclei ( Fig. 9A and C ). This phenotype is strikingly similar to that of myoblasts expressing dominant-active FoxO1a-TM (5).
To address whether the large multinucleated myotubes that formed during the differentiation of primary cGKI Ϫ/Ϫ myoblasts in vitro were the product of deregulated fusion rather than endo-reduplication events, cGKI Ϫ/Ϫ myoblasts were stained with two different cell tracker dyes, mixed, and then transferred to differentiation medium. All large cGKI Ϫ/Ϫ myotubes contained two-colored nuclei in an overall 1-to-1 ratio. Therefore, loss of cGKI specifically accelerated the rate of myoblast cell fusion (Fig. 9B) , a phenotype remarkably akin to that of myoblasts engineered to overexpress dominant-active FoxO1a (5). Attempts to prove that the accelerated fusion phenotype of cGKI Ϫ/Ϫ myoblasts was intrinsic were unsuccessful, because overexpression of wild-type cGKI␣, like that of cGKI-CA, was toxic to cGKI Ϫ/Ϫ (or wild-type) primary myoblasts (data not shown). Finally, cGKI loss was not associated with alterations in muscle cell differentiation per se, as evidenced by the facts that the temporal expression of the late muscle-specific marker myosin heavy chain was not perturbed (Fig. 9D ) and the overall levels of FoxO1a were unaffected by loss of cGKI (data not shown). Therefore, cGKI functions downstream of FoxO1a to orchestrate myoblast cell fusion.
Conclusions. The molecular mechanisms mediating mammalian cell-to-cell fusion events have heretofore been enigmatic. In myoblasts, some of the initial events are now coming into focus with the identification of the FoxO1a-to-cGKI␣ regulatory pathway. We propose that this pathway acts as an essential rheostat of fusion events by maintaining a critical balance between a transcription factor (FoxO1a) and its neg- ϩ/ϩ and cGKI Ϫ/Ϫ myoblasts showed that loss of cGKI has no effect on the levels and timing of expression of a late (myosin heavy chain) marker during muscle cell differentiation, nor does it affect expression of FoxO1a. FastGreen-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis membranes were used as loading and transfer controls. ative regulator (cGKI␣), resulting in proper fusion and muscle development. In differentiating myoblasts, FoxO1a accumulates in the nucleus and induces the transcription of target genes involved in membrane remodeling and fusion ( Fig. 10 ) (5, 25) . Its targets now also include cGKI, a kinase that in turn negatively regulates FoxO1a transcriptional activity. The essential nature of this negative-feedback loop is best illustrated by the in vitro overfusion phenotype observed in cGKI Ϫ/Ϫ myoblasts, which closely mimics the behavior of myoblasts expressing dominant-active FoxO1a. Following its induction by FoxO1a, cGKI␣ kinase activity is likely triggered by an essential spike in intracellular cGMP levels that accompanies myoblast cell fusion (9) . cGKI␣ inhibits FoxO1a function in a rather unique manner, by phosphorylating residues that directly inhibit its DNA binding activity. This phosphorylation effectively squelches the transcriptional activity of FoxO1a to ensure the proper production of fusion components during differentiation (Fig. 10) . This scenario classifies FoxO1a as an additional regulator of muscle cell differentiation, where it controls not only the expression of key genes involved in cytoskeletal remodeling and fusion (5) but also that of its dedicated negative regulator cGKI. Notably, this program occurs in parallel with those transcriptional programs directed by myogenic basic helix-loop-helix transcription factors (e.g., MyoD, myogenin, Myf4, and Myf6) (24), which are not affected by alterations in FoxO1a or cGKI activity. However, since both pathways are required for proper muscle development, an as yet unknown cross talk mechanism must exist that coordinates muscle cell differentiation and fusion. 
